Literature DB >> 22946067

PSA testing in general practice.

Fraser Hodgson1, Zuzana Obertová, Charis Brown, Ross Lawrenson.   

Abstract

INTRODUCTION: In New Zealand, prostate-specific antigen (PSA) testing has increased significantly (275 000 tests/year). Controversy exists around PSA testing as part of an unorganised screening programme. AIM: To look at the use of PSA testing in a sample of general practices and investigate the reasons GPs undertake PSA testing.
METHODS: Five Waikato general practices investigated looking at PSA laboratory tests of men ≥40 years in 2010 compared against GP notes. Testing rates, reasons for testing, histology and referral/s were examined for different age groups. A questionnaire was sent to the GPs to determine their views on PSA testing.
RESULTS: One in four men aged 40+ years had a PSA test in 2010. Of these men, 71% were asymptomatic. More than half of men tested aged 70+ years were asymptomatic. Ten percent of all PSA tests were elevated. Twenty-one of 23 prostate cancers were diagnosed following an elevated PSA test: more than 80% of these men had histories of prostate pathology or lower urinary tract symptoms. The questionnaire confirmed that GPs believe in the benefits of PSA screening and it also showed they had difficulty in providing patients with information about pros and cons of PSA testing. DISCUSSION: All GPs in this study tested asymptomatic men. GPs in this study value PSA screening and believe that it reduces mortality rates. However, although PSA tests were most frequently done on asymptomatic patients, the majority of patients subsequently diagnosed with prostate cancer had been tested because of symptoms or had previous prostate problems.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22946067

Source DB:  PubMed          Journal:  J Prim Health Care        ISSN: 1172-6156


  6 in total

1.  Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand.

Authors:  Zuzana Obertová; Nina Scott; Charis Brown; Fraser Hodgson; Alistair Stewart; Michael Holmes; Ross Lawrenson
Journal:  BMC Fam Pract       Date:  2014-08-26       Impact factor: 2.497

2.  An examination of clinical differences between carriers and non-carriers of chromosome 8q24 risk alleles in a New Zealand Caucasian population with prostate cancer.

Authors:  Karen S Bishop; Dug Yeo Han; Nishi Karunasinghe; Megan Goudie; Jonathan G Masters; Lynnette R Ferguson
Journal:  PeerJ       Date:  2016-03-01       Impact factor: 2.984

3.  SNP-SNP interactions as risk factors for aggressive prostate cancer.

Authors:  Venkatesh Vaidyanathan; Vijay Naidu; Nishi Karunasinghe; Anower Jabed; Radha Pallati; Gareth Marlow; Lynnette R Ferguson
Journal:  F1000Res       Date:  2017-05-03

4.  A genetic risk assessment for prostate cancer influences patients' risk perception and use of repeat PSA testing: a cross-sectional study in Danish general practice.

Authors:  Jacob Fredsøe; Pia Kirkegaard; Adrian Edwards; Peter Vedsted; Karina Dalsgaard Sørensen; Flemming Bro
Journal:  BJGP Open       Date:  2020-06-23

5.  Bacterial communities of Aphis gossypii and Myzus persicae (Hemiptera: Aphididae) from pepper crops (Capsicum sp.).

Authors:  Jenny Johana Gallo-Franco; Diana Nataly Duque-Gamboa; Nelson Toro-Perea
Journal:  Sci Rep       Date:  2019-04-08       Impact factor: 4.379

6.  General practitioners' reflections on using PSA for diagnosis of prostate cancer. A qualitative study.

Authors:  Olav Thorsen; Eirik Viste; Torgeir Gilje Lid; Svein R Kjosavik
Journal:  Scand J Prim Health Care       Date:  2022-04-12       Impact factor: 3.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.